# OnCo record taletrectinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/taletrectinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "taletrectinib" ;
  schema:name "Taletrectinib"@en ;
  schema:description "A ROS1 lung-cancer pill approved in 2025 that works in the brain and after crizotinib, with fewer dizziness-type side effects than repotrectinib."@en ;
  schema:url <https://onco.cc/drugs/taletrectinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Taletrectinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q135111475> ;
  schema:citation <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule ROS1 TKI (next generation, CNS-penetrant)" ;
  schema:alternateName "Ibtrozi" ;
  onco:approval "CN 2025: ROS1-positive NSCLC", "US 2025: Locally advanced or metastatic ROS1-positive NSCLC" ;
  onco:related <https://onco.cc/biomarkers/ros1-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ros1-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ros1/> ;
  onco:companies <https://onco.cc/companies/nuvation-bio/>, <https://onco.cc/companies/innovent/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/> ;
  onco:trials <https://onco.cc/trials/nct07154706/>, <https://onco.cc/trials/nct06564324/>, <https://onco.cc/trials/nct04919811/> .